Pramiracetam

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pramiracetam
Pramiracetam.svg
Pramiracetam3d.png
Systematic (IUPAC) name
N-[2-(Diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
Clinical data
Trade names Neupramir, Pramistar, Remen
AHFS/Drugs.com International Drug Names
Legal status
  • US: Not FDA approved
Routes Oral
Identifiers
CAS number 68497-62-1 N
ATC code N06BX16
PubChem CID 51712
ChemSpider 46801 YesY
UNII 4449F8I3LE YesY
ChEMBL CHEMBL159776 YesY
Chemical data
Formula C14H27N3O2 
Mol. mass 269.383 g/mol
 N (what is this?)  (verify)

Pramiracetam is a central nervous system stimulant and nootropic agent belonging to the racetam family of drugs. It is used in Eastern European countries and has the brand names Remen (Parke-Davis), Neupramir (Lusofarmaco), or Pramistar (Firma).[1] It is not approved for any use by the US Food and Drug Administration or by the European Medicines Agency.

Pramiracetam has been studied as a potential treatment for memory loss associated with Alzheimer's disease[2][3] and for cognitive problems resulting from brain injury.[4]

History[edit]

Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US).

References[edit]

  1. ^ Axel Kleemann, Jürgen Engel, Bernd Kutscher and Dietmar Reichert (2000). Pharmaceutical Substances (4th ed.). ISBN 978-1-58890-031-9. 
  2. ^ Vreese, De (1996). "Memory training and drug therapy act differently on memory and metamemory functioning: evidence from a pilot study". Gerontol Geriatr. 22: 9–22. doi:10.1016/0167-4943(96)86906-8. PMID 18653001. Results showed that objective memory gains of the two groups receiving pramiracetam were significantly larger than that of the MT and CTR groups. 
  3. ^ Claus, JJ (April 1991). "Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetam". Neurology 41 (4): 570–574. doi:10.1212/wnl.41.4.570. PMID 2011259. Eight patients evidenced a best dose in the dose-finding phase, but in the subsequent replication phase only two again improved to a similar degree. 
  4. ^ McLean A Jr, Cardenas DD, Burgess D, Gamzu E (1991). "Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia". Brain Inj. 5 (4): 375–380. doi:10.3109/02699059109008110. PMID 1786500.